CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ÀüÈ«Àç
  • ¾Ï¼¾ÅÍÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °£¾Ï/Ãé´ãµµ¾Ï
  • Á÷ À§: ºÎ±³¼ö(¾Ï¼¾ÅÍÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
203 (±¹¿Ü)SCI Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma
202 (±¹³»)KCI È£»ê±¸Áõ°¡Áõ°ú PDGFRB À¯ÀüÀÚ Àç¹è¿­À» º¸ÀÎ °ñ¼ö Á¾¾ç 1¿¹
201 (±¹¿Ü)SCI Normalization of Tumor Vessels by Tie2 Activationand Ang2 Inhibition Enhances Drug Delivery andProduces a Favorable Tumor Microenvironment
200 (±¹³»)SCOPUS A case of atypical hemolytic uremic syndrome associated with the c.1273C£¾T mutation in the complement C3 gene
199 (±¹¿Ü)SCI Predictors of general discomfort, limitations in activities of daily living and intention of a second donation in unrelated hematopoietic stem cell donation
198 (±¹¿Ü)SCI Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
197 (±¹¿Ü)SCI Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
196 (±¹³»)SCI Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea
195 (±¹¿Ü)SCIE Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
194 (±¹¿Ü)SCIE Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients
ÀÌÀüÆäÀÌÁö À̵¿ 11 12 13 14 15 16 17 18 19 20 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729